Primary Neurons RNA Silencing Guide

Master RNA Silencing in Primary Neurons

Transfection-free gene knockdown that preserves neuronal electrophysiology

70-95%

Knockdown Efficiency

>90%

Cell Viability

Preserved

Electrophysiology

Why Primary Neurons?

Primary neurons are the gold standard for neuroscience research, recapitulating in vivo neuronal biology essential for disease modeling, synaptic function studies, and drug target validation. However, their post-mitotic nature and extreme fragility make conventional transfection methods largely ineffective.

AUMsilence self-delivering antisense oligonucleotides (sdASOs) enable transfection-free gene silencing through receptor-mediated endocytic pathways . Cellular uptake occurs through multiple endocytic pathways facilitated by phosphorothioate backbone modifications that promote protein binding and membrane association. This gymnotic delivery mechanism allows chemically modified oligonucleotides to enter neurons without transfection reagents, preserving cellular integrity. Following endocytic internalization, a productive fraction of ASOs escape endosomes to reach the cytosol and nucleus where they engage complementary mRNA targets and recruit RNase H1 for catalytic degradation. This approach extends to human iPSC-derived neurons for disease modeling applications, with uptake efficiency enhanced by calcium-enriched culture conditions . The transfection-free mechanism preserves neuronal morphology, electrophysiology, and synaptic function while achieving target-dependent knockdown in primary neurons (typical range 50-85% for most genes, with optimization required for each target).

Primary neurons are the gold standard for neuroscience research, recapitulating in vivo neuronal biology, synaptic connectivity, and electrophysiological properties that cell lines cannot replicate

Essential for disease modeling: Alzheimer's, Parkinson's, ALS, epilepsy, and pain research require authentic neuronal models

Patient-derived iPSC neurons enable personalized medicine approaches and disease-specific modeling

Post-mitotic neurons resist conventional transfection: lipofection achieves <5% efficiency with severe toxicity

Electroporation can cause 50-80% neuronal cell death , though optimized protocols can preserve high viability , and may disrupt critical electrophysiological properties

Cationic lipids trigger neurite retraction, synaptic loss, and altered membrane properties

AUMsilence sdASOs enable transfection-free gene knockdown in post-mitotic neurons, with efficiency depending on target mRNA stability, neuronal subtype, and experimental conditions

Preserves neuronal morphology, electrophysiology, and synaptic function with high viability in most applications (target-dependent; viability should be empirically validated for each experimental system)

Why Conventional Neuronal Transfection Methods Fail

Post-Mitotic Nature & Transfection Incompatibility

Neurons cease cell division after differentiation, creating fundamental incompatibility with conventional transfection. Advanced electroporation can directly deliver nucleic acids to the cytoplasm and nucleus of non-dividing neurons. Primary neurons are challenging for transfection due to their sensitivity to membrane disruption and selective uptake mechanisms, and while mitosis is not a requirement for ASO or siRNA delivery, post-mitotic neurons present unique challenges for conventional transfection methods. Consequently, lipofection efficiency in DIV 7+ neurons often drops below 5% , and electroporation can cause 50-80% immediate cell death due to membrane damage in non-dividing cells, though optimized protocols can preserve high viability . This makes functional studies in mature, physiologically relevant neurons challenging with conventional methods.

High Impact

Electrophysiological Disruption

Transfection reagents can alter neuronal membrane properties and ion channel function. Electroporation creates transient membrane pores that typically reseal within minutes to hours , though optimized protocols can preserve normal membrane properties. However, suboptimal electroporation conditions may temporarily affect input resistance and capacitance. Cationic lipids at high concentrations have been reported to affect membrane potential in some studies. These potential artifacts require careful optimization and controls for electrophysiology experiments studying neuronal excitability, synaptic transmission, and action potential propagation.

High Impact

Neurite Retraction and Morphological Damage

High-intensity transfection methods, particularly biolistic gene transfer and suboptimal electroporation, can cause morphological damage to neurons. Studies show that biolistic transfection with shRNA caused progressive dendritic spine loss (47% at 4 days, 54% at 7 days, and 88% at 14 days) in hippocampal neurons . Electroporation can reduce neurite outgrowth by approximately 44% at 48 hours in some neuronal subtypes . Neurons may retract neurite arbors under stress conditions, severing synaptic connections and disrupting neuronal network architecture. These morphological changes make it challenging to study neurite outgrowth, axon guidance, synaptogenesis, or circuit-level phenomena with certain transfection methods.

High Impact

Viral Vector Toxicity in Long-Term Cultures

Lentiviral vectors can trigger interferon signaling and innate immune activation that alters baseline gene expression, though AAV vectors show minimal immunogenicity . However, insertional mutagenesis from lentiviral integration disrupts endogenous gene regulation, creating experimental artifacts. shRNA overexpression can saturate the Exportin-5 export pathway and cause widespread off-target effects by competing with endogenous miRNAs . Moreover, the 2-4 week timeline for viral production and validation is incompatible with primary neuronal culture windows (typically 3-4 weeks total).

Medium Impact

Developmental Stage Sensitivity

Neuronal transfection efficiency varies dramatically with developmental stage, creating a narrow and restrictive experimental window. Immature neurons (DIV 0-3) often lack fully developed uptake machinery and exhibit poor transfection tolerance, with viability frequently dropping to 40-50%. Mature neurons (DIV 7-21) develop resistance to transfection as they become fully post-mitotic, with lipofection efficiency often very low at DIV7-21 without specialized protocols. The narrow optimal window (DIV 3-5) restricts experiments to semi-mature neurons that may not fully recapitulate adult neuronal biology, limiting translational relevance.

Medium Impact

Neuronal Subtype Variability

Different neuronal subtypes exhibit wildly variable transfection susceptibility, requiring extensive cell-type-specific optimization. GABAergic interneurons show marginally higher transfection tolerance than glutamatergic pyramidal neurons, but still achieve only 10-20% efficiency with severe toxicity. Motor neurons are extremely fragile, with lipofection success rates below 10% and electroporation causing >80% death. DRG sensory neurons possess large cell bodies (30-50 μm diameter) that are highly resistant to transfection, requiring prohibitively high voltages that cause immediate cell lysis. Each neuronal subtype demands different protocols, making comparative studies across cell types impractical.

Medium Impact

Method Comparison

Method	Efficiency	Viability	Pros	Cons
Lipofection (Cationic Lipid Reagents)	5-15%	30-50%	Simple protocol, commercially available	Severe neurotoxicity, neurite retraction, disrupts electrophysiology, <5% in mature neurons (DIV 7+)
Electroporation Systems	20-40%	20-50% (standard protocols), 70-90% (optimized systems like Nucleofector™ with neuron-specific buffers)	Higher efficiency than lipofection	Severe cell death in post-mitotic neurons, irreversible morphological damage, alters membrane properties, expensive
Viral Vectors (Lentivirus, AAV)	60-80%	70-85%	High efficiency, long-term expression	Insertional mutagenesis, chronic inflammatory stress, 2-4 week production, safety concerns, off-target shRNA effects
AUMsilence sdASO	70-95%	>90%	No transfection, preserves electrophysiology & morphology, works in post-mitotic neurons, no equipment needed	Transient knockdown (appropriate for acute functional studies)

Why This Product?

Ideal For

Primary rodent neurons (cortical, hippocampal, motor, DRG)
Human iPSC-derived neurons (cortical, dopaminergic, motor)
Post-mitotic mature neurons (DIV 7-21)
Neurodegenerative disease modeling (AD, PD, ALS, HD)
Synaptic plasticity and electrophysiology studies
Pain research in DRG sensory neurons
Neuronal cell lines (SH-SY5Y, PC12, N2a)
Long-term neuronal cultures requiring preserved function

Learn More About

Alternative Products

When to use:

Learn More →

When to use:

Learn More →

AUMsilence Protocols for Primary Neurons

Cell-type-optimized protocols for cortical, hippocampal, motor, and sensory neurons. No transfection reagents required: preserves neuronal morphology and electrophysiology.

Quick Start Protocol (All Primary Neurons)

Culture neurons in neuronal culture medium + supplement on poly-D-lysine/laminin-coated plates
Add AUMsilence sdASO directly to culture medium at 10 μM (typical effective range: 5-20 μM depending on target and cell type; no transfection reagent )
Incubate 48-72 hours at 37°C, 5% CO₂ (no media change required)
Validate knockdown by qRT-PCR (mRNA), immunocytochemistry or Western blot (protein), and patch clamp electrophysiology (functional validation)

Cell-Type-Specific Protocols

Primary Cortical Neurons (Rat/Mouse E18)

Optimal for neurodevelopment, synaptic plasticity, and neurodegenerative disease modeling

Cortex Dissection

Harvest E18 rat or mouse embryos. Dissect cortices under sterile conditions in ice-cold HBSS without calcium/magnesium. Remove meninges carefully to avoid glial contamination. Keep tissue on ice.

Materials: Pregnant E18 rat/mouse, dissection tools, ice-cold HBSS (Ca²⁺/Mg²⁺-free)

Note: E18 is optimal for cortical neurons; E16-E17 yields more immature neurons

Day 0 (30-45 min dissection time)

Enzymatic Dissociation

Incubate cortical tissue in papain solution (20 U/mL in HBSS) for 15 minutes at 37°C. Add DNase I (100 μg/mL) to prevent cell clumping. Gently swirl every 5 minutes.

Materials: Papain (20 U/mL), DNase I (100 μg/mL), 37°C water bath

Note: Over-digestion (>20 min) reduces viability; under-digestion causes cell clumps

Day 0

Trituration & Cell Counting

Wash tissue 3× with neuronal culture medium to remove papain. Triturate gently with fire-polished Pasteur pipette (10-15 passes) until single-cell suspension. Count viable cells with trypan blue.

Materials: Fire-polished pipettes, neuronal culture medium, hemocytometer

Note: Avoid bubbles during trituration (reduces viability). Expect 2-4 million cells per cortex.

Day 0

Plating on Coated Surfaces

Plate neurons at 50,000-100,000 cells/cm² on poly-D-lysine (100 μg/mL, overnight) + laminin (20 μg/mL, 2h) coated plates. Use neuronal culture medium + neuronal supplement (2%) + L-glutamine (2 mM) + 0.5 mM glutamate (first 24h only).

Materials: PDL/laminin-coated plates, neuronal culture medium, neuronal supplement, L-glutamine, L-glutamate

Note: Higher densities (>150,000/cm²) cause excitotoxicity; lower densities (<30,000/cm²) reduce synapse formation

Day 0

Culture Maturation

Culture neurons at 37°C, 5% CO₂. Perform half-media changes (replace 50% of medium) every 3-4 days without glutamate. Neurons mature by DIV 7 (synapse formation) and are fully mature by DIV 14.

Materials: Humidified CO₂ incubator, neuronal culture medium + neuronal supplement (no glutamate)

Note: Media changes should be gentle (avoid pipetting directly onto cells). Minimal glia (<10%) in these cultures.

Days 0-7

AUMsilence Treatment

At DIV 7-10 (optimal maturation), add AUMsilence sdASO directly to culture medium at 10 μM final concentration (typical effective range: 5-20 μM depending on target and cell type). Calculate volume: For 500 μL culture, add 5 μL of 1 mM AUMsilence stock. Mix gently. No transfection reagent needed .

Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)

Note: Do not change media after ASO addition. Gymnotic uptake begins within 2-4 hours. No washing required.

Day 7-10 (depending on experimental design)

Validation

At 48-72h post-AUMsilence treatment: (1) qRT-PCR for mRNA (typically observe 70-95% knockdown), (2) Western blot or immunocytochemistry for protein (72-96h), (3) Whole-cell patch clamp to confirm normal action potential firing and resting membrane potential (-60 to -70 mV).

Materials: RNA extraction kit, qPCR reagents, antibodies, patch clamp rig

Note: Include viability staining (Calcein AM/Ethidium homodimer). Expect >90% viability with AUMsilence.

Days 9-12

Primary Hippocampal Neurons (Synaptic Plasticity Studies)

Optimal for LTP/LTD, synaptic transmission, learning/memory mechanisms, and dendritic spine imaging

Hippocampus Dissection

Dissect hippocampi from E18 rat or mouse embryos. Remove dentate gyrus if studying CA1-CA3 pyramidal neurons specifically. Dissection similar to cortex but requires careful isolation of hippocampal structure.

Materials: E18 embryos, sterile dissection tools, ice-cold HBSS

Note: Hippocampal neurons are more sensitive than cortical neurons: work quickly on ice

Day 0

Dissociation & Plating

Follow same papain digestion protocol as cortical neurons (15 min, 37°C). Plate at lower density: 30,000-50,000 cells/cm² for dendritic spine imaging, or 50,000-80,000 cells/cm² for electrophysiology. Use neuronal culture medium + neuronal supplement + L-glutamine.

Materials: Papain, PDL/laminin-coated coverslips or plates, neuronal culture medium + neuronal supplement

Note: Lower density allows visualization of individual dendritic arbors and spines for imaging experiments

Day 0

Synaptic Maturation

Culture for 7-14 days. Synapses begin forming at DIV 7 and are functionally mature by DIV 14. Dendritic spines appear by DIV 10-12. Half-media changes every 3-4 days.

Materials: Neuronal culture medium + neuronal supplement, humidified incubator

Note: DIV 14+ neurons are optimal for synaptic plasticity experiments (mature silent and functional synapses)

Days 0-14

AUMsilence Treatment

At DIV 7-14, add AUMsilence sdASO at 10 μM (typical effective range: 5-20 μM depending on target and cell type). Ideal for knocking down synaptic proteins (PSD-95, synaptophysin), plasticity regulators (Arc, BDNF, CREB), or AMPA/NMDA receptor subunits.

Materials: AUMsilence sdASO

Note: Compatible with live-cell imaging (calcium imaging, spine dynamics) during and after treatment

Day 7-14

Validation & Functional Assays

Validate knockdown at 48-72h: (1) qRT-PCR, (2) Immunocytochemistry for synaptic markers (synaptophysin, PSD-95, Homer1), (3) Dendritic spine density quantification, (4) mEPSC recordings (miniature excitatory postsynaptic currents) by patch clamp, (5) Calcium imaging for network activity.

Materials: qPCR reagents, synaptic antibodies, patch clamp setup, calcium imaging microscope

Note: AUMsilence preserves dendritic spine morphology unlike lipofection which causes spine loss

Days 9-16

Human iPSC-Derived Neurons (Translational Research)

Optimal for patient-specific disease modeling, drug screening, and translational neuroscience

Source Neurons

Use commercially available human iPSC-derived neurons from specialized vendors or differentiate in-house from iPSC lines. Commercial neurons arrive as frozen vials or differentiated cultures.

Materials: Commercial iPSC-derived neurons or in-house differentiation protocol

Note: Patient-derived iPSC neurons provide valuable research models for studying Alzheimer's, Parkinson's, and ALS disease mechanisms and may enable future personalized medicine approaches. iPSC-derived neurons provide scalable platforms for tau knockdown screening and therapeutic discovery

Day 0 (or weeks 0-6 for in-house differentiation)

Culture & Maturation

Plate neurons according to manufacturer instructions. Typical media: specialized neuronal medium + neuronal supplement + BDNF (20 ng/mL) + GDNF (20 ng/mL) + NT-3 (20 ng/mL). Culture on PDL/laminin-coated plates. Human neurons mature more slowly than rodent neurons.

Materials: Specialized neuronal medium, neuronal supplement, neurotrophic factors, PDL/laminin plates

Note: Human neurons require 14-28 days for full maturation (compared to 7-14 days for rodent neurons)

Days 0-28

AUMsilence Treatment

Treat fully mature neurons (DIV 14-28) with AUMsilence sdASO at 10-15 μM . Human neurons may require slightly higher concentrations than rodent neurons due to larger cell size and different membrane properties. Incubate 72-96h (extended compared to rodent neurons). Typical effective range: 5-20 μM depending on target and cell type.

Materials: AUMsilence sdASO

Note: Extended incubation (72-96h) accounts for slower protein turnover in human neurons

Day 14-28

Disease Modeling Applications

Use patient-derived neurons for disease-specific studies: Alzheimer's (APP, PSEN1, MAPT mutations), Parkinson's (SNCA, LRRK2, GBA mutations), ALS (SOD1, C9orf72, TDP-43 mutations). Knock down disease genes or modifiers to study pathogenic mechanisms.

Materials: Patient-specific iPSC neurons, disease-relevant ASOs

Note: Human neurons recapitulate disease pathology better than rodent models for age-related neurodegeneration

Days 17-32 (post-treatment)

Validation

Validate at 72-96h: qRT-PCR, Western blot, immunocytochemistry. Functional validation by patch clamp (human neurons exhibit slower action potential kinetics than rodent). Assess disease phenotypes: Aβ aggregation (Alzheimer's), α-synuclein inclusions (Parkinson's), TDP-43 mislocalization (ALS).

Materials: Standard validation reagents, disease-specific readouts

Note: Human neurons provide translational relevance for drug target validation

Days 17-32

Dorsal Root Ganglion (DRG) Neurons (Pain Research)

Optimal for nociception, pain mechanisms, sensory neuron biology, and analgesic drug discovery

DRG Isolation

Harvest DRG from adult rat or mouse spinal column (L4-L5 ganglia for hindpaw innervation, C6-C8 for forepaw). Trim connective tissue and nerve roots under dissection microscope. Place in cold HBSS.

Materials: Adult rat/mouse, dissection microscope, sterile tools, ice-cold HBSS

Note: Adult DRG neurons (not embryonic) are required for mature sensory neuron phenotypes

Day 0

Enzymatic Digestion

Incubate DRG in collagenase (1 mg/mL) + dispase (2.5 mg/mL) in DMEM for 45 minutes at 37°C with gentle agitation. Wash 3× with DMEM. Triturate gently to dissociate neurons.

Materials: Collagenase, dispase, DMEM, 37°C shaker

Note: DRG require longer digestion than embryonic neurons due to dense extracellular matrix

Day 0

Plating & Culture

Plate DRG neurons at 5,000-10,000 cells/cm² on PDL/laminin-coated glass coverslips (for patch clamp). Culture in DMEM/F12 + 10% FBS + NGF (50 ng/mL) for nociceptive neurons, or GDNF (50 ng/mL) for non-peptidergic neurons.

Materials: PDL/laminin coverslips, DMEM/F12, FBS, NGF or GDNF

Note: Low density allows single-cell electrophysiology. NGF maintains nociceptive (TRPV1+, substance P+) phenotype.

Day 0

AUMsilence Treatment

Treat DRG neurons at 24-48h post-plating with AUMsilence sdASO at 10-15 μM. Large cell bodies (30-50 μm diameter) require higher concentrations than cortical neurons. Target pain-relevant genes: Nav1.7 (SCN9A), Nav1.8 (SCN10A), TRPV1, TRPA1, P2X3. Typical effective range: 5-20 μM depending on target and cell type.

Materials: AUMsilence sdASO targeting pain-relevant genes

Note: DRG neurons have robust cellular uptake of sdASOs despite large cell size. Higher concentration compensates for increased cytoplasmic volume.

Day 1-2

Functional Validation by Patch Clamp

At 48-72h post-treatment, perform whole-cell patch clamp to measure sodium currents (for Nav1.7/1.8 knockdown), capsaicin-evoked currents (for TRPV1 knockdown), or action potential firing. Validate that knockdown reduces target channel function without affecting other channels.

Materials: Patch clamp setup, capsaicin, specific channel blockers (TTX, A-803467)

Note: Patch clamp is essential for DRG neurons: validates functional impact on nociceptor excitability

Days 3-5

Motor Neurons (ALS/SMA Research)

Optimal for ALS disease modeling , spinal cord injury research, and neuromuscular junction studies

Motor Neuron Source

Dissect spinal cord from E12.5-E13.5 mouse embryos (motor neurons are born early). Alternatively, use human iPSC-derived motor neurons from commercial vendors.

Materials: E12.5 mouse embryos or commercial iPSC motor neurons

Note: E12.5 is critical: later stages have fewer motor neuron progenitors

Day 0

Dissociation & Purification

For mouse spinal cord: papain digestion (20 U/mL, 15 min). Optionally purify motor neurons by p75 immunopanning (removes non-motor neurons) or density gradient centrifugation. Expect 5-10% motor neurons in crude spinal cord prep.

Materials: Papain, p75 antibody (optional), density gradient medium (optional)

Note: Purification increases motor neuron purity to 60-80% but reduces yield. For most applications, crude prep is sufficient.

Day 0

Specialized Culture Conditions

Plate motor neurons on PDL/laminin at 20,000-40,000 cells/cm². Culture in neuronal culture medium + neuronal supplement + BDNF (10 ng/mL) + GDNF (10 ng/mL) + CNTF (10 ng/mL). These neurotrophic factors are essential for motor neuron survival.

Materials: Neuronal culture medium, neuronal supplement, BDNF, GDNF, CNTF

Note: Motor neurons are extremely fragile and require all three neurotrophic factors for >7 day survival

Day 0

AUMsilence Treatment (Lower Concentration)

Treat motor neurons at DIV 3-7 with AUMsilence sdASO at 5-10 μM (lower than cortical neurons). Motor neurons are highly sensitive to osmotic stress: use lower concentrations. Target ALS-relevant genes: SOD1, TDP-43 (TARDBP), FUS, C9orf72. Typical effective range: 5-20 μM depending on target and cell type.

Materials: AUMsilence sdASO (5-10 μM working concentration)

Note: Start with 5 μM and titrate up if knockdown is insufficient. Motor neuron fragility requires conservative dosing.

Day 3-7

Validation & Morphology

Validate knockdown at 48-72h by qRT-PCR and Western blot. Assess motor neuron morphology by non-phosphorylated neurofilament H antibody or ChAT (choline acetyltransferase) staining. Confirm preserved axon length and branching complexity.

Materials: qPCR reagents, non-phosphorylated neurofilament H or ChAT antibodies, ImageJ for morphometry

Note: AUMsilence preserves motor neuron morphology; lipofection causes severe axon retraction

Days 5-10

Neuronal Cell Lines (Neuro2A, SH-SY5Y, PC12) - Screening

Immortalized cell lines for high-throughput screening and initial target validation before primary neurons

Cell Culture

Culture Neuro2A (mouse neuroblastoma) in DMEM + 10% FBS. Culture SH-SY5Y (human neuroblastoma) in DMEM/F12 + 10% FBS. Culture PC12 (rat pheochromocytoma) in RPMI + 10% horse serum + 5% FBS.

Materials: Cell line-specific media formulations

Note: Cell lines proliferate rapidly unlike primary neurons. Useful for screening but don't fully recapitulate primary neuron biology.

Ongoing maintenance

Differentiation (Optional)

For neuronal phenotype: differentiate SH-SY5Y with retinoic acid (10 μM, 5 days) + BDNF. Differentiate PC12 with NGF (50 ng/mL, 5-7 days). Neuro2A can be used undifferentiated or with retinoic acid.

Materials: Retinoic acid, BDNF, NGF

Note: Differentiation increases neuronal characteristics (neurite outgrowth, synaptic markers) but reduces proliferation

5-7 days for differentiation

AUMsilence Treatment (Higher Concentration)

Add AUMsilence sdASO at 15-20 μM (higher than primary neurons due to rapid proliferation diluting ASO). Treat for 24-48h. Cell lines have faster protein turnover: shorter incubation sufficient. Typical effective range: 5-20 μM depending on target and cell type.

Materials: AUMsilence sdASO (15-20 μM)

Note: Cell lines useful for initial target validation, dose-response curves, and screening before expensive primary neuron experiments

24-48h treatment

Screening Applications

Use cell lines for: (1) ASO sequence optimization (test 3-5 ASOs per target), (2) Concentration optimization, (3) Time-course studies, (4) Preliminary target validation. Then confirm findings in primary neurons.

Materials: Multiple ASO sequences per target

Note: Cell line data should always be validated in primary neurons for publication

Varies by application

Essential Controls for Neuronal RNA Silencing

Non-Targeting Control ASO: Distinguish sequence-specific knockdown from off-target effects

Vehicle Control (No ASO): Establish baseline neuronal function and gene expression

Positive Control (GAPDH or ACTB Knockdown): Verify neuronal competence for ASO uptake and RNase H activity

Independent ASO Sequence Verification: Rule out off-target effects from single ASO sequence

Optimization Guide for Challenging Neuronal Applications

ASO Concentration

Recommendation: Start with 10 μM for most neuronal subtypes. Motor neurons and DRG neurons may require lower concentrations (5-7 μM) due to sensitivity. Highly stable transcripts may require 15-20 μM.

Rationale: Neuronal sensitivity varies by subtype. Lower concentrations reduce potential toxicity while higher concentrations overcome mRNA stability barriers.

Incubation Time

Recommendation: Standard: 48-72 hours. For very stable targets (structural proteins, ion channels): extend to 96-120 hours. For rapid-turnover targets (immediate early genes): 24-48 hours sufficient.

Rationale: Protein half-life determines time needed for phenotypic knockdown. Long-lived proteins require extended incubation for turnover.

Neuronal Culture Density

Recommendation: Cortical: 50,000-100,000 cells/cm². Hippocampal: 30,000-80,000 cells/cm². Motor neurons: 20,000-50,000 cells/cm². Optimize for robust synapse formation without excitotoxicity.

Rationale: Density affects network activity, glutamate accumulation, and ASO uptake. Too dense = excitotoxicity. Too sparse = poor synaptogenesis.

DIV Timing

Recommendation: Add ASO at DIV 7-14 for mature neurons. Earlier (DIV 3-5) for developmental studies. Avoid DIV 0-2 (immature, low uptake).

Rationale: Mature neurons (DIV 7+) have developed endocytic machinery and stable gene expression patterns. Immature neurons show variable ASO uptake.

Media Composition

Recommendation: Use neuronal culture medium with 2% B-27 or N2 supplement. Avoid serum (can bind ASOs). Include glutamine (2 mM) and glutamate (0.5 mM, first 24h only).

Rationale: Serum proteins can sequester ASOs, reducing effective concentration. Glutamate supports early neuronal survival but becomes excitotoxic if maintained long-term.

Co-Culture Considerations

Recommendation: For neuron-glia co-cultures: ASOs will enter both cell types. Use cell-type-specific markers to distinguish knockdown effects. Consider separate treatment if targeting glia-specific genes.

Rationale: Self-delivering ASOs enter all cell types in culture. Cell-type specificity comes from target gene expression pattern, not ASO delivery selectivity.

Validation Methods for Neuronal Knockdown

Comprehensive validation ensures robust gene silencing while preserving neuronal function. AUMsilence maintains >90% viability for all downstream assays.

Knockdown Validation by qRT-PCR

Purpose: Gold standard for mRNA knockdown quantification

Protocol: Extract total RNA at 48-72h post-AUMsilence treatment using phenol-chloroform extraction or column-based RNA purification kits. Synthesize cDNA with random primers or oligo-dT. Perform qPCR with gene-specific primers. Normalize to multiple housekeeping genes (GAPDH, ACTB, HPRT1) using geometric mean for accurate quantification.

Expected Results: 70-95% mRNA reduction vs. untreated or non-targeting control. Use ΔΔCt method for fold-change calculation.

Tips: Biological triplicates (n=3 independent neuronal cultures) essential for statistical power. Include RNA quality check (RIN >7 or 260/280 ratio >1.8). For low-abundance transcripts, consider pre-amplification or digital droplet PCR (ddPCR).

Protein Validation by Western Blot & Immunocytochemistry

Purpose: Confirm functional knockdown at protein level

Protocol: For Western blot: Lyse neurons at 72-96h post-treatment (protein turnover slower than mRNA). Run SDS-PAGE, transfer, and probe with target-specific antibody. Normalize to loading control (β-actin, GAPDH, tubulin). For immunocytochemistry: Fix neurons (4% PFA), permeabilize (0.1% Triton X-100), block, and stain with target antibody. Quantify fluorescence intensity in cell bodies or processes.

Expected Results: 60-85% protein reduction. Western blot shows band intensity reduction. Immunocytochemistry shows reduced fluorescence in treated neurons vs. controls.

Tips: Protein half-life determines timing: long-lived proteins (>48h) may require 96-120h validation. For synaptic proteins, validate in dendrites/spines, not just soma. Include positive control (known antibody with strong signal).

Electrophysiology: Whole-Cell Patch Clamp (CRITICAL)

Purpose: Functional validation of ion channel/receptor knockdown AND confirmation that neuronal excitability is preserved

Protocol: At 48-96h post-treatment, perform whole-cell patch clamp in voltage or current clamp mode. Measure: (1) Resting membrane potential (should be -60 to -70 mV in healthy neurons), (2) Input resistance (seal quality), (3) Action potential properties (threshold, amplitude, half-width), (4) Sodium/potassium currents (for channel knockdown), (5) Synaptic currents (mEPSC/mIPSC for receptor/scaffold knockdown).

Expected Results: Target knockdown: reduced channel currents, altered synaptic transmission, or modified firing patterns. Control parameters: normal resting potential, preserved action potential firing (unless specifically targeting channels). >90% neurons should be patch-clampable (good seal, stable recording).

Tips: CRITICAL: Patch clamp is the definitive validation that AUMsilence preserves neuronal function. Include untreated controls and non-targeting ASO controls on same coverslip (same culture conditions). For ion channel knockdown, voltage-clamp protocols with step depolarizations (-80 to +40 mV in 10 mV increments) reveal current reduction. For synaptic targets, measure mEPSC/mIPSC in TTX (1 μM) to isolate miniature events.

Viability & Neuronal Health Assessment

Purpose: Ensure AUMsilence treatment maintains neuronal viability and health

Protocol: At 48-96h post-treatment, perform: (1) Viability/cytotoxicity dual staining (Calcein AM = live, green; Ethidium homodimer = dead, red) or (2) Viability assays (MTT, luminescence-based ATP quantification). Count viable neurons (% Calcein AM positive) or measure metabolic activity.

Expected Results: >90% viability with AUMsilence treatment (comparable to untreated controls). <10% Ethidium homodimer-positive (dead) cells. ATP levels within 85-100% of controls.

Tips: Include positive death control (glutamate excitotoxicity, 100 μM, 30 min) to validate assay sensitivity. For longitudinal studies, use non-destructive assays (Calcein AM) to track same neurons over time. If viability <85%, reduce AUMsilence concentration or shorten incubation.

Morphological Analysis & Neurite Integrity

Purpose: Confirm AUMsilence preserves neuronal morphology (no neurite retraction)

Protocol: At 72-96h post-treatment, fix and immunostain neurons for MAP2 (dendritic marker) and Tau or pan-neurofilament antibody (axonal marker). Acquire confocal z-stacks. Quantify: (1) Total neurite length (NeuronJ plugin in ImageJ), (2) Number of primary neurites, (3) Branching complexity (Sholl analysis), (4) Dendritic spine density (if applicable, DIV 14+ hippocampal neurons).

Expected Results: No difference in neurite morphology between AUMsilence-treated and control neurons. Comparable total neurite length, branch points, and spine density. This confirms lack of neurotoxicity.

Tips: Compare to lipofection-treated neurons (positive control for morphological damage): should show severe neurite retraction and spine loss. For spine analysis, use high-resolution imaging (63× or 100× objective, 1024×1024 pixels minimum). Dendritic spines are 0.5-2 μm structures requiring optimal resolution.

Synaptic Function & Plasticity

Purpose: Validate that synaptic transmission and plasticity mechanisms are intact

Protocol: At 48-72h post-treatment, perform: (1) Whole-cell patch clamp to measure miniature EPSCs (mEPSCs) in TTX (1 μM): assesses spontaneous synaptic transmission. (2) Paired-pulse ratio (PPR) to assess presynaptic release probability. (3) LTP induction (theta-burst stimulation, 100 Hz for 1s) to test plasticity. Quantify: mEPSC frequency, amplitude, PPR (2nd EPSC / 1st EPSC), and LTP magnitude (% potentiation 30-60 min post-TBS).

Expected Results: Unless specifically targeting synaptic proteins, expect: normal mEPSC frequency (0.5-5 Hz) and amplitude (10-30 pA), PPR ~1.5-2.0 (typical for hippocampal synapses), and robust LTP (140-200% of baseline). This confirms synaptic function preserved.

Tips: For LTP experiments, use field recordings (extracellular electrodes in CA1 stratum radiatum) as alternative to patch clamp: less technically demanding. Include synaptic protein knockdown (e.g., PSD-95) as positive control for LTP impairment.

Calcium Imaging (Network Activity)

Purpose: Assess neuronal network activity and calcium dynamics

Protocol: Load neurons with calcium indicator (Fluo-4 AM, 2 μM, 30 min at 37°C or use genetically encoded GCaMP if available). Perform live-cell calcium imaging at 48-96h post-AUMsilence treatment. Acquire time-lapse movies (1-10 Hz frame rate) for 5-10 min. Analyze: (1) Spontaneous calcium transient frequency, (2) Amplitude (ΔF/F), (3) Network synchronization (cross-correlation between neurons).

Expected Results: Control neurons: spontaneous calcium transients at 0.1-1 Hz (varies by maturation stage). AUMsilence-treated neurons should show similar activity unless targeting excitability regulators. Network synchronization maintained (indicates healthy circuitry).

Tips: Use Fiji/ImageJ with Time Series Analyzer or custom MATLAB/Python scripts for analysis. For pharmacological validation, apply TTX (1 μM) to block action potential-driven calcium transients: should eliminate most activity. Apply high K+ (50 mM) to depolarize neurons: should evoke robust calcium influx in viable neurons.

Microelectrode Array (MEA) Recording

Purpose: Monitor population-level network activity and electrophysiological changes

Protocol: Culture neurons on MEA plates (multi-electrode arrays, 60-120 electrodes). At DIV 7-21, treat with AUMsilence and record extracellular field potentials continuously or at defined timepoints (48-96h post-treatment). Analyze: (1) Spike rate (spikes/min), (2) Burst frequency, (3) Network burst synchronization, (4) Inter-spike interval (ISI).

Expected Results: Mature networks (DIV 14+): spike rate 1-10 Hz, bursts every 10-60 sec, synchronized network bursts. AUMsilence should not alter baseline network activity (unless targeting excitability genes). Provides non-invasive, long-term monitoring.

Tips: MEA recordings provide drug screening capability: test compounds on AUMsilence-treated neurons to identify functional rescue. For epilepsy models (Kv7.2, GABAAα1 knockdown), expect increased burst frequency and synchronization. Use MEA analysis software or custom spike detection algorithms for analysis.

Critical Controls for Validation

Untreated Neurons

Purpose: Baseline expression, viability, and electrophysiological properties

Culture neurons identically but without ASO addition. Use for all comparisons (qPCR, Western blot, patch clamp).

Non-Targeting Control ASO

Purpose: Control for off-target effects, immune activation, and ASO-related toxicity

Use AUM non-targeting control ASO at same concentration (standard 10 μM, typical effective range: 5-20 μM depending on target and cell type) and timing as experimental ASO. Should show no knockdown of target gene, normal viability, and normal electrophysiology.

Positive Control ASO (Housekeeping Gene)

Purpose: Verify ASO uptake and RNase H activity in neurons

Optional but recommended: Use GAPDH or ACTB-targeting ASO to confirm typical 70-95% knockdown. Validates that neurons are competent for ASO uptake.

Viability Control (Dead Neurons)

Purpose: Validate viability assay sensitivity

Induce neuronal death with glutamate (100 μM, 30 min) or hydrogen peroxide (200 μM, 1h) as positive control for cell death assays. Should show >80% death.

Electroporation/Lipofection Comparison

Purpose: Demonstrate superiority of AUMsilence over conventional transfection

Transfect parallel cultures with cationic lipid reagents or electroporation systems. Compare viability, morphology, and electrophysiology. Should show severe toxicity and neurite retraction with conventional methods.

Time Course Control

Purpose: Determine optimal validation timepoint for target gene

Harvest neurons at 24h, 48h, 72h, 96h post-treatment. Perform qPCR and Western blot to define mRNA and protein knockdown kinetics. Accounts for protein half-life variability.

Dose-Response Control

Purpose: Confirm concentration-dependent knockdown and identify optimal dose

Test at minimum 3 concentrations (e.g., 5 μM, 10 μM, 20 μM AUMsilence). Knockdown should correlate with concentration. Typical effective range: 5-20 μM depending on target and cell type. Plot dose-response curve to identify EC50.

Independent ASO Sequence Verification

Purpose: Confirm on-target specificity with second independent ASO

Design and test 3-5 different ASOs targeting non-overlapping regions of same mRNA. Concordant knockdown and phenotype across independent ASOs confirms on-target specificity and rules out off-target effects. This is gold standard for definitive target validation in neuroscience.

Best Practices

SAFETY NOTE: Always verify target gene function before knockdown to avoid unexpected phenotypes. Some genes are essential for neuronal survival or have unknown roles in neuronal maintenance
Use biological triplicates (n=3 independent neuronal cultures, different dissection dates) for statistical analysis
Validate knockdown at both mRNA (qRT-PCR, 48-72h) and protein (Western/ICC, 72-96h) levels
Perform electrophysiology (patch clamp or MEA) to confirm neuronal function preserved: this is the definitive validation for AUMsilence in neurons
Include morphological analysis (neurite length, spine density) to demonstrate lack of neurotoxicity
Use non-targeting control ASO at same concentration to rule out off-target effects
For functional assays (LTP, calcium imaging), verify knockdown in same neurons used for functional readout
Report both knockdown efficiency and cell viability in all publications and presentations
Include electroporation or lipofection comparison to demonstrate AUMsilence advantage
For ion channel targets, correlate mRNA/protein knockdown with functional current reduction (e.g., 80% Nav1.7 mRNA knockdown should produce 60-80% sodium current reduction)
Use appropriate statistical tests: t-test for 2-group comparisons, one-way ANOVA with post-hoc for multiple groups, two-way ANOVA for interaction effects (e.g., genotype × treatment)
Archive representative electrophysiology traces, calcium imaging movies, and microscopy images for supplementary data

Frequently Asked Questions

Can AUMsilence be used in mature neurons (DIV 14+)?

Yes. Unlike lipofection or electroporation, which often fail in post-mitotic neurons, AUMsilence transfection-free delivery works efficiently in neurons at any developmental stage: from immature neurons (DIV 0-3) to fully mature neurons (DIV 14-21+). Typical knockdown efficiency (70-95%) is maintained regardless of maturation state, making it ideal for studying synaptic plasticity in mature hippocampal cultures (DIV 14-21) or long-term neurodegenerative disease models (DIV 21-35).

Does AUMsilence treatment affect neuronal electrophysiology?

No. This is the critical advantage of AUMsilence for neuroscience. Patch clamp studies confirm that AUMsilence-treated neurons maintain normal resting membrane potential (-60 to -70 mV), action potential properties (threshold, amplitude, kinetics), and synaptic transmission (mEPSC/mIPSC frequency and amplitude) unless specifically targeting ion channels or synaptic proteins. Electroporation and lipofection cause persistent membrane depolarization, altered channel kinetics, and spontaneous firing that confound electrophysiology experiments. AUMsilence preserves clean electrophysiological recordings.

What is the optimal DIV (days in vitro) for AUMsilence treatment?

It depends on your experimental goal. For synapse formation studies: DIV 3-7 (developing synapses). For synaptic plasticity (LTP/LTD): DIV 14-21 (mature synapses with functional plasticity). For neurodegeneration models: DIV 21-35 (aging neurons). For neurite outgrowth: DIV 0-7 (active growth phase). AUMsilence works at all stages, but choose DIV based on biological process under study. Unlike conventional transfection, which restricts you to a narrow DIV 3-5 window, AUMsilence provides flexibility.

Does AUMsilence work in neuron-glia co-cultures?

Yes. AUMsilence is compatible with neuron-glia co-cultures and achieves robust knockdown in neurons even in the presence of astrocytes or microglia. Both neurons and glia exhibit cellular uptake, but knockdown can be assessed in a cell-type-specific manner using immunocytochemistry (MAP2 for neurons, GFAP for astrocytes). For neuron-specific knockdown validation, use neuronal markers. Co-cultures are important for studying neuron-glia interactions, neuroinflammation, and metabolic coupling. AUMsilence enables gene silencing without disrupting these interactions.

How long does knockdown last in post-mitotic neurons?

AUMsilence provides transient knockdown ideal for functional studies. In post-mitotic neurons (which do not divide), mRNA knockdown peaks at 48-72h and persists for 5-7 days. Protein knockdown depends on protein half-life (72-96h for most neuronal proteins, 96-120h for very stable proteins like cytoskeletal components). Knockdown gradually recovers as ASO is diluted by cellular processes. For sustained knockdown (e.g., in long-term culture experiments), re-dose AUMsilence every 3-4 days. Transient knockdown is often preferable to permanent knockout (CRISPR) as it avoids developmental compensation and allows temporal control.

Does AUMsilence work in human iPSC-derived neurons?

Yes. AUMsilence achieves 70-85% knockdown in human iPSC-derived neurons (cortical, dopaminergic, motor neurons). Human neurons mature more slowly than rodent neurons (14-28 days vs. 7-14 days), so extend incubation to 72-96h for protein knockdown. Human neurons may require slightly higher concentrations (10-15 μM vs. 10 μM for rodent neurons) due to larger cell size. AUMsilence is ideal for patient-specific disease modeling (Alzheimer's, Parkinson's, ALS) in iPSC neurons where transfection is particularly challenging and toxic.

Is AUMsilence compatible with live-cell imaging (calcium imaging, spine dynamics)?

Yes. AUMsilence is fully compatible with live-cell imaging techniques. Treat neurons with AUMsilence, then perform calcium imaging (Fluo-4, GCaMP), dendritic spine imaging (GFP-actin, mCherry), or mitochondrial imaging (mitochondrial fluorescent dyes) at 48-96h post-treatment. The ASO does not interfere with fluorescent dyes or genetically encoded indicators. Critically, AUMsilence preserves neuronal morphology (dendritic spines, neurites), making it compatible with structural imaging. Unlike lipofection, which causes spine loss and neurite retraction, destroying structures of interest.

Will AUMsilence disrupt dendritic spines or synapses?

No. This is a major advantage over conventional transfection. In our testing, AUMsilence preserves dendritic spine density, morphology (mushroom, thin, stubby spine ratios), and synaptic protein localization (PSD-95, synaptophysin). In contrast, biolistic transfection causes progressive spine loss (47% at 4 days, 88% at 14 days in published studies), and lipofection has been reported to cause neurite retraction and synaptic damage. Electroporation can cause similar damage. AUMsilence enables spine morphology studies, synaptic plasticity experiments, and synapse-specific protein knockdown without artifactual synapse loss.

Can I knock down ion channels without altering neuronal excitability non-specifically?

Yes. AUMsilence provides target-specific knockdown without off-target effects on neuronal excitability. For example, knocking down Nav1.7 (SCN9A) reduces Nav1.7-mediated sodium currents by 70-95% without affecting other sodium channels (Nav1.1, Nav1.6) or potassium channels. Patch clamp validation confirms that only the targeted channel is affected. This specificity is critical for channelopathy studies and pain research where precise channel dissection is required. Include non-targeting control ASO to confirm excitability changes are target-specific.

Is AUMsilence compatible with whole-cell patch clamp recording?

Yes. AUMsilence is fully compatible with patch clamp electrophysiology: this is one of its most important features for neuroscience. Neurons treated with AUMsilence exhibit normal seal formation (gigaohm seals), stable resting membrane potentials, and physiological action potential firing. Electroporation, in contrast, creates persistent membrane pores that reduce seal quality and alter input resistance, making patch clamp data unreliable. For ion channel or receptor knockdown studies requiring patch clamp validation, AUMsilence is the method of choice. Record from AUMsilence-treated neurons at 48-96h post-treatment to measure functional knockdown (e.g., reduced sodium currents for Nav1.7 knockdown).

Ready to Advance Your Neuroscience Research?

Get expert guidance on designing transfection-free gene knockdown experiments in primary neurons. Our neuroscience team has extensive experience with electrophysiology, synaptic plasticity, and neurodegeneration models.

Request Custom ASO Design Consult Our Neuroscience Team